Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 8648172Abstract: The present invention provides antibodies that simultaneously bind the ?- and ?-subunits of an intact MUC1 protein, and methods for making and using such antibodies.Type: GrantFiled: November 16, 2011Date of Patent: February 11, 2014Assignees: Biomodifying, LLC, Ramot at Tel Aviv University Ltd.Inventors: Daniel B. Rubinstein, Daniel H. Wreschner
-
Patent number: 8648046Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: November 17, 2010Date of Patent: February 11, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Patent number: 8648173Abstract: The application provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.Type: GrantFiled: May 17, 2007Date of Patent: February 11, 2014Assignee: Genentech, Inc.Inventors: Yan Wu, Wei-Ching Liang, Ryan Jefferson Watts, Anil Durgadas Bagri
-
Patent number: 8648171Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.Type: GrantFiled: August 7, 2007Date of Patent: February 11, 2014Assignee: The UAB Research FoundationInventors: Randall S. Davis, Max D. Cooper
-
Publication number: 20140037623Abstract: The invention relates to pharmaceutical and vaccine compositions comprising an antibody binding specifically to selected peptides of EBV protein BARF1.Type: ApplicationFiled: September 30, 2013Publication date: February 6, 2014Inventor: Tadamasa OOKA
-
Patent number: 8642277Abstract: Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.Type: GrantFiled: July 29, 2010Date of Patent: February 4, 2014Assignees: Albert Einstein College of Medicine of Yeshiva University, Massachusetts Institute of Technology, Cornell UniversityInventors: John S. Condeelis, Thomas E. Rohan, Frank B. Gertler, Joan G. Jones
-
Patent number: 8637027Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: November 3, 2011Date of Patent: January 28, 2014Assignee: arGEN-X B.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Patent number: 8629248Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.Type: GrantFiled: May 28, 2010Date of Patent: January 14, 2014Assignee: Roche GlycArt AGInventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
-
Patent number: 8629247Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.Type: GrantFiled: April 14, 2010Date of Patent: January 14, 2014Assignee: Proscan RX Pharma Inc.Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Patent number: 8624001Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD 19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hAl9 VH sequence.Type: GrantFiled: June 17, 2013Date of Patent: January 7, 2014Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8623366Abstract: The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.Type: GrantFiled: August 23, 2010Date of Patent: January 7, 2014Assignee: Labrys Biologics, Inc.Inventors: Ariel Ates Pios, Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller
-
Patent number: 8617846Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: November 22, 2011Date of Patent: December 31, 2013Assignee: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Publication number: 20130336969Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.Type: ApplicationFiled: March 2, 2011Publication date: December 19, 2013Applicant: INSTITUT DE CANCEROLOGIE DE L'OUESTInventors: Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
-
Patent number: 8603466Abstract: The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies.Type: GrantFiled: March 29, 2007Date of Patent: December 10, 2013Assignee: King's College LondonInventors: Jasvinder-Paul Singh Banga, Jacqueline Ann Gilbert, Deborah Dunn-Walters, Carolyn Padoa
-
Patent number: 8603479Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: GrantFiled: May 21, 2013Date of Patent: December 10, 2013Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8603465Abstract: The present invention relates to method for treating medical disorders mediated by mutations in the APC gene by administering an IGF1R inhibitor. Such disorders include, for example, familial adenomatous polyposis (FAP).Type: GrantFiled: August 6, 2007Date of Patent: December 10, 2013Assignee: Merck Sharp & Dohme, Corp.Inventor: Siu-Long Yao
-
Patent number: 8603476Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, whichType: GrantFiled: January 9, 2009Date of Patent: December 10, 2013Assignee: Astellas Pharma Inc.Inventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Patent number: 8603473Abstract: The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.Type: GrantFiled: April 9, 2008Date of Patent: December 10, 2013Assignee: Biogen Idec MA Inc.Inventors: Scott Glaser, Mitchell Reff, Tzung-Horng Yang, Xiufeng Wu, Paul Chinn
-
Patent number: 8591889Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: GrantFiled: April 1, 2009Date of Patent: November 26, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Patent number: 8580263Abstract: Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.Type: GrantFiled: November 20, 2007Date of Patent: November 12, 2013Assignees: The Regents of the University of California, Fox Chase Cancer CenterInventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
-
Patent number: 8580929Abstract: The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.Type: GrantFiled: August 24, 2012Date of Patent: November 12, 2013Assignee: The Hong Kong University of Science and TechnologyInventors: Nancy Y. Ip, William M. W. Cheung
-
Publication number: 20130296188Abstract: Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice.Type: ApplicationFiled: November 11, 2011Publication date: November 7, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Bing Lim, Wencai Zhang
-
Patent number: 8569459Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.Type: GrantFiled: May 23, 2012Date of Patent: October 29, 2013Assignee: Medimmune, LLCInventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
-
Publication number: 20130281672Abstract: Herein is reported a method for determining whether a re-usable chromatography column packing, which is used at least for the second time in a purification step of a purification of a polypeptide, has reduced separation efficacy in said purification step of said purification of said polypeptide, comprising the following steps: a) identifying and determining the experimental data of an inert change of at least one physicochemical parameter of a mobile phase passing through said re-usable chromatography column packing, b) determining the parameters of a function of formula I by fitting the experimental data of the inert change of the physicochemical parameter of the at least second use, c) determining the difference between the experimental data of the inert change of the physicochemical parameter of the at least second use and the function of formula I with the parameters determined in step b), d) calculating the difference between the maximum value and the minimum value of the difference determined in step c)Type: ApplicationFiled: June 19, 2013Publication date: October 24, 2013Inventors: Anton Belousov, Thomas Dams, Benjamin Gerwat
-
Publication number: 20130280257Abstract: The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention.Type: ApplicationFiled: November 9, 2012Publication date: October 24, 2013Inventor: Liliane GOETSCH
-
Patent number: 8552155Abstract: This document provides methods and materials related to anti-Pyk2 antibodies. For example, anti-Pyk2 antibodies, methods for making anti-Pyk2 antibodies, and methods for using an anti-Pyk2 antibody to inhibit glioma cell migration are provided.Type: GrantFiled: May 28, 2009Date of Patent: October 8, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventors: Christopher A. Lipinski, Joseph C. Loftus
-
Patent number: 8545845Abstract: Antibodies against various domains of laminin-332 are discussed herein. The antibodies reduce the adhesion and matrix binding properties of laminin-332, inhibiting tumor growth and metastasis in vivo. Pharmaceutical compositions and methods of using the antibodies for diagnostic, prophylactic, and/or therapeutic purposes are disclosed.Type: GrantFiled: June 18, 2009Date of Patent: October 1, 2013Inventors: Karl Tryggvason, Sirpa Anne Kristiina Salo
-
Patent number: 8546546Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.Type: GrantFiled: July 3, 2008Date of Patent: October 1, 2013Assignee: Forerunner Pharma Research Co., Ltd.Inventor: Kiyotaka Nakano
-
Publication number: 20130252826Abstract: Large deletions have been identified in the PMS2 gene in patients. The large deletions predispose the patients to Lynch syndrome associated cancers. Thus, methods for detecting the genetic variants are provided which can be used in detecting a predisposition to cancer.Type: ApplicationFiled: March 22, 2013Publication date: September 26, 2013Applicant: Myriad Genetics, Inc.Inventors: Karla Bowles, Benoit Leclair, Saradha Rajamani, Jeffrey T. Trost, Jack W. Landon, Benjamin B. Roa
-
Publication number: 20130236465Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.Type: ApplicationFiled: October 24, 2011Publication date: September 12, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Min Zhou, Hai Wang, Bizhi Shi, Shengli Yang, Hongyang Wang, Jianren Gu
-
Patent number: 8529891Abstract: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.Type: GrantFiled: November 22, 2010Date of Patent: September 10, 2013Assignee: Trustees of Tufts CollegeInventors: Daniel G Jay, Brenda K Eustace, Takashi Sakurai
-
Patent number: 8524460Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: April 8, 2011Date of Patent: September 3, 2013Assignee: The Regents of the UniversityInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Publication number: 20130224208Abstract: An object is to provide glioma treatment and testing methods, and a method for delivering a desired substance to a glioma, all of which target a molecule specifically expressed in a glioma, as well as drugs and so forth used in these methods. It has been found out that targeting Eva1 or Ceacam1 enables glioma treatment and testing, and delivering of a desired substance to a glioma.Type: ApplicationFiled: September 29, 2011Publication date: August 29, 2013Applicant: RIKENInventor: Toru Kondo
-
Patent number: 8518887Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: June 25, 2010Date of Patent: August 27, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Patent number: 8518405Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: GrantFiled: October 8, 2010Date of Patent: August 27, 2013Assignee: The University of North Carolina at CharlotteInventor: Pinku Mukherjee
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 8512712Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: GrantFiled: February 29, 2012Date of Patent: August 20, 2013Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Publication number: 20130212721Abstract: The present invention aims to provide a novel reagent for tumor testing and a novel pharmaceutical composition for tumor prevention. The present invention provides a reagent for tumor detection, which comprises a probe for the FEAT gene or amplification primers for the FEAT gene, or an antibody against the FEAT protein or a fragment of the antibody. Moreover, the present invention also provides a pharmaceutical composition for tumor prevention, which is configured to use the FEAT gene or the FEAT protein as a tumor marker to thereby recognize tumor cells.Type: ApplicationFiled: August 15, 2011Publication date: August 15, 2013Applicant: Kyushu University, National University CorporationInventor: Atsushi Takahashi
-
Patent number: 8507442Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: GrantFiled: June 20, 2011Date of Patent: August 13, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Patent number: 8501175Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.Type: GrantFiled: November 10, 2008Date of Patent: August 6, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, So-Young Choi, Young-Soon Jang, Ji Hyun Park, Eun-Jung Song, Jung Yu, Myung-Ho Sohn, Jae Won Jeon, Joon-Goo Jung, Sungsub Kim, Myeoung Hee Jang
-
Patent number: 8501181Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.Type: GrantFiled: December 28, 2011Date of Patent: August 6, 2013Assignee: Dyax Corp.Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
-
Patent number: 8501471Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen.Type: GrantFiled: June 9, 2010Date of Patent: August 6, 2013Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 8492520Abstract: The invention relates to specific amino acid sequences which have been determined to be target epitope for antibodies, in particular, for a G250 antibody.Type: GrantFiled: October 31, 2008Date of Patent: July 23, 2013Assignee: Wilex AGInventors: Thorsten Wöhl, Volker Böttger
-
Patent number: 8481687Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: April 8, 2011Date of Patent: July 9, 2013Assignee: Aveo Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 8481688Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.Type: GrantFiled: May 11, 2011Date of Patent: July 9, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Zhigang Weng, William M. Winston, Jr., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Publication number: 20130171148Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: May 27, 2011Publication date: July 4, 2013Applicant: GENMAB A/SInventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
-
Publication number: 20130171063Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.Type: ApplicationFiled: June 1, 2011Publication date: July 4, 2013Inventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott